Whitefish, MT / April 14, 2014 / Premier Biomedical, Inc. and the Wild West of Modern Medicine
Many diseases are caused by the presence of specific molecular compounds within the body, such as metastatic cancer cells in many different types of cancer or tau proteins in Alzheimer's disease. Companies like Seattle Genetics Inc. (SGEN) are developing monoclonal antibodies designed to target cancer cells, while other biotechnology firms like Pfizer Inc. (PFE) have failed in the fight against AD.
Premier Biomedical Inc. (BIEI) is an early-stage biotechnology company that is taking a less conventional approach in treating these conditions and others. Through a process known as sequential dialysis, the company’s goal is to directly remove metastatic cancer cells, tau proteins, and other harmful substances from the blood for blood-borne diseases and from the cerebral spinal fluid for neurological diseases and ultimately physically remove the underlying causes of the diseases.
In this article, we'll take a look at the company, its unique business model, and why investors may want to take a closer look at the stock.
Unique Approach to Treating Disease
Premier Biomedical is a pioneer in using sequential dialysis techniques in order to directly remove harmful molecular compounds from the body. The technology takes blood or other bodily fluid from a patient, removes disease-causing molecules, and returns the purified fluid back to the body, thus successfully manipulating the body's immune system. The process is similar to how traditional dialysis machines work in taking and purifying a patient's blood and is covered by some 20 provisional patent applications.
The company's sequential dialysis techniques will initially target cancer, multiple sclerosis (MS), Alzheimer's disease, and traumatic brain injury ("TBI"). Early tests at the University of Texas at El Paso have proven that the technology is effective in removing substances from blood and cerebral spinal fluid. The key will be determining whether or not these results can be replicated in humans in order to completely remove disease. The company plans to begin such clinical tests on humans as early as later this year as a follow-up to their successful experiments on breast cancer in mice presented at the Annual Symposium of the American Association for Cancer Research in San Diego on April 4-9, 2014.
The sequential dialysis approach differs greatly from conventional treatments for these diseases. Cancer treatments have largely been focused on indiscriminant killing of both good and diseased cells in localized areas using chemotherapy or modern monoclonal antibodies that remain relatively unproven. Alzheimer's disease and TBI remain two areas where current treatments only address the symptoms and not the causes.
Partnership Model De-Risks Process
Many pharmaceutical and biotechnology companies face a large amount of risk, since they must undergo expensive clinical trials for a chance at approval. According to the Tufts Center for the Study of Drug Development, the capitalized costs of a drug approval in the United States amount to $1.3 billion on average. The greater amount of R&D cost has also resulted in fewer regulatory approvals lately and a "drying up" of the pool of new drug candidates.
Premier Biomedical aims to mitigate these risks through a partnership business model. Through an agreement with the University of Texas at El Paso, the company has access to a $45 million lab and almost unlimited technical expertise to conduct a large portion of its early research. A separate agreement with the U.S. Department of Defense then provides further access to unlimited technical expertise and resources, large-scale animal model creation and clinical testing capabilities necessary to move towards human trials. The company also touts the ability of their DOD partner to fast track beneficial discoveries through the FDA.
Once early-stage research is completed in conjunction with these two partners, Premier Biomedical aims to license its technology to large pharmaceutical companies while retaining the largest royalties possible. Many of these pharmaceutical companies are facing near-term patent expirations on some of their largest drugs, creating a pressing need to bolster their clinical pipelines and set the stage for future approvals. As an alternate, the company is preparing to manufacture and distribute their medical products to direct channels while reducing the entry barriers for adopting this new technology via leasing of the necessary equipment at cost to hospitals and clinics.
Potential Investment Opportunity
Premier Biomedical represents an attractive investment opportunity given its early laboratory successes, its unique approach to treating disease, low overhead, and its low-risk business model. With a market capitalization of just $14.7 million, the company trades at a fraction of its potential valuation if it's successful in bringing drugs to market and the pathway to getting there may require less dilution than many other companies in the space.
There are also a number of near-term catalysts that could help increase awareness of the company over the coming quarters. In a recent investor presentation, management indicated that it would be publishing multi-monthly press releases, journal articles and other materials, as well as participating in symposiums, seminars and conferences in order to further advance its position, strategy and developments to the major sports organizations as well as the investing public.
- Company Website
- Investor Presentation
- Recent SEC Filings
- Get Updates on Premier Biomedical here: http://www.tdmfinancial.com/emailassets/biei/biei_landing.php
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx